Seretide®/Advair treatment effective in COPD

Study results show that treatment with Seretide/Advair (salmeterol/fluticasone propionate ) slows the progression of Chronic Obstructive Pulmonary Disease (COPD) by lowering a patient’s rate of lung function decline compared with those receiving placebo.

SkyePharmas Third Flutiform Phase III Study meets endpoints

SkyePharma have announced that its third Phase III trial of Flutiform in asthma patients has met its primary endpoints.

AstraZeneca file sNDA for Symbicort for Asthma in children

AstraZeneca have filed supplemental New Drug Application to the FDA for approval of Symbicort (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol in paediatric patients ages 6 to 11 years old.

Exacerbations in COPD reduced with Advair

Advair Diskus 250/50 (fluticasone propionate and salmeterol) has been shown to reduce exacerbationsin Chronic Obstruvtive Pulmonary Disease (COPD) patients by 30%

AstraZeneca submit sNDA for Symbicort for COPD

AstraZeneca have submitted a supplementary NDA for Symbicort (budesonide/formoterol fumarate dihydrate) for the treatment of patients with Chronic Obstructive Pulmonary Disease (COPD). Symbicort is already approved for the long-term maintenance treatment of asthma.

FDA approves Advair 250/50 for COPD

The FDA has approved Advair Diskus 250/50 (fluticasone propionate 250 mcg and salmeterol 50 mcg inhalation powder) for the reduction of exacerbations in patients with chronic obstructive pulmonary disease (COPD). This is the first drug to be approved by the FDA to reduce COPD exacerbations.

Sepracor settles patent dispute with Breath Ltd over Xopenex

Sepracor have settled a patent dispute with Breath Ltd allowing Breath to launch generic versions of Xopenex under terms of an exclusive license commencing on August 20, 2012.